Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis

被引：24

作者：

Lingscheid, Tilman ^{[1
,2
,3
]}

Kinzig, Martina ^{[4
]}

Krueger, Anne ^{[2
,3
,5
]}

Mueller, Nils ^{[2
,3
,5
]}

Boelke, Georg ^{[2
,3
,5
]}

Tober-Lau, Pinkus ^{[1
,2
,3
]}

Muenn, Friederike ^{[1
,2
,3
]}

Kriedemann, Helene ^{[1
,2
,3
]}

Witzenrath, Martin ^{[1
,2
,3
,6
]}

Sander, Leif E. ^{[1
,2
,3
,6
,7
]}

Soergel, Fritz ^{[4
,8
]}

Kurth, Florian ^{[1
,2
,3
,9
]}

机构：

[1] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany

[2] Free Univ Berlin, Berlin, Germany

[3] Humboldt Univ, Berlin, Germany

[4] IBMP Inst Biomed & Pharmaceut Res, Nurnberg, Germany

[5] Charite Univ Med Berlin, Dept Nephrol & Intens Care, Berlin, Germany

[6] DZL, German Ctr Lung Res, Berlin, Germany

[7] Berlin Inst Hlth, Berlin, Germany

[8] Univ Duisburg Essen, West German Heart & Vasc Ctr, Inst Pharmacol, Essen, Germany

[9] Bernhard Nocht Inst Trop Med, Dept Trop Med, Hamburg, Germany

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2022年 / 66卷 / 11期

关键词：

COVID-19; end-stage renal disease; hemodialysis; nirmatrelvir/ritonavir; Paxlovid; PLASMA;

D O I：

10.1128/aac.01229-22

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Nirmatrelvir/ritonavir is an effective antiviral therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage renal disease (ESDR) due to a lack of data. We investigated the pharmacokinetics of nirmatrelvir/ritonavir (150 mg/100 mg twice a day) in four patients with ESRD undergoing hemodialysis. Nirmatrelvir peak concentrations ranged from 4,563 to 7,898 ng/ mL and declined after hemodialysis. Concentrations were up to 4-fold higher but still within the range known from patients without ESRD, without accumulation of nirmatrelvir after the end of treatment.

引用

页数：4

共 50 条

[21] Pharmacokinetics of rosiglitazone in patients with end-stage renal disease
Thompson-Culkin, K
Zussman, B
Miller, AK
Freed, MI
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2002, 30 (04) : 391 - 399
[22] Nefopam Pharmacokinetics in Patients with End-Stage Renal Disease
Mimoz, Olivier
Chauvet, Stephane
Gregoire, Nicolas
Marchand, Sandrine
Le Guern, Marie-Emmanuelle
Saleh, Ashraf
Couet, William
Debaene, Bertrand
Levy, Rene H.
ANESTHESIA AND ANALGESIA, 2010, 111 (05): : 1146 - 1153
[23] Nirmatrelvir-ritonavir for nonhospitalized patients with COVID-19
LeBras, Marlys
Crawley, Alex
Legge, Marc
Takaya, Satchan
Lee, Stephen
Regier, Loren
CANADIAN FAMILY PHYSICIAN, 2023, 69 (08) : 546 - 549
[24] Pharmacokinetics of gentamicin in patients with end-stage renal disease undergoing conventional intermittent hemodialysis: A comparative study between diabetic and nondiabetic patients
Irshaid, Yacoub M.
Al-Homrany, Mohammed A.
El Sherif, Assem K.
Omar, Haider
THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 533 - 533
[25] Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment
Manitpisitkul, Prasarn
Curtin, Christopher R.
Shalayda, Kevin
Wang, Shean-Sheng
Ford, Lisa
Heald, Donald L.
EPILEPSY RESEARCH, 2014, 108 (05) : 891 - 901
[26] Nirmatrelvir-ritonavir for COVID-19
McDonald, Emily G.
Lee, Todd C.
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (06) : E218 - E218
[27] Dosing of Aminoglycosides in Chronic Kidney Disease and End-Stage Renal Disease Patients Treated with Intermittent Hemodialysis
Halouzkova, Barbora Agatha
Hartinger, Jan Miroslav
Kratky, Vojtech
Tesar, Vladimir
Slanar, Ondrej
KIDNEY & BLOOD PRESSURE RESEARCH, 2022, 47 (07): : 448 - 458
[28] Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis
Shiue, Harn J.
Taylor, Maria
Sands, Kara A.
ANNALS OF PHARMACOTHERAPY, 2017, 51 (10) : 862 - 865
[29] Persistence of coronavirus disease 2019 (COVID-19) in patients with end-stage renal disease; an unrecognized phenomenon?
Onuigbo, Macaulay Amechi Chukwukadibia
JOURNAL OF RENAL INJURY PREVENTION, 2021, 10 (01): : 1 - 3
[30] Nirmatrelvir and Ritonavir Combination in COVID-19 Patients With Advanced Chronic Kidney Disease
Lafont, Emmanuel
Blez, Damien
Bildan, Marc-Antoine
Veyer, David
Pere, Helene
Puech, Julien
Kably, Benjamin
Cheminet, Geoffrey
Pouchot, Jacques
Thervet, Eric
Peytavin, Gilles
Lazareth, Helene
CLINICAL INFECTIOUS DISEASES, 2024, 79 (03) : 798 - 800

← 1 2 3 4 5 →